Seeking Alpha

Merck's (MRK +1.1%) MK-3475 treatment performed well in a Phase IB study of 85 patients with...

Merck's (MRK +1.1%) MK-3475 treatment performed well in a Phase IB study of 85 patients with advanced melanoma, with 43 experiencing an "objective response." Of those, eight had a "complete response." Merck now plans to start Phase II trials of MK-3475. The drug is part of a new class of agents called PD-1 inhibitors, which help the immune system to overcome tumors. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs